Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| DCS (Crossover) | Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, for 6 weeks. | 0 | None | 0 | 2 | 0 | 2 | View |
| Open Label DCS | Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, for 8 weeks. | 0 | None | 0 | 2 | 0 | 2 | View |
| PLACEBO (CROSSOVER) | Both participants received placebo for 6 weeks. | 0 | None | 0 | 2 | 0 | 2 | View |
| Second Open Label DCS | Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks. D-cycloserine: Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks. | 0 | None | 0 | 2 | 0 | 2 | View |